Promis Neurosciences Stock Performance
| PMN Stock | USD 13.10 2.55 16.29% |
On a scale of 0 to 100, ProMIS Neurosciences holds a performance score of 8. The company holds a Beta of -0.34, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning ProMIS Neurosciences are expected to decrease at a much lower rate. During the bear market, ProMIS Neurosciences is likely to outperform the market. Please check ProMIS Neurosciences' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether ProMIS Neurosciences' historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ProMIS Neurosciences are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, ProMIS Neurosciences displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.82) | Five Day Return (31.93) | Year To Date Return 78.29 | Ten Year Return (83.03) | All Time Return (99.29) |
Last Split Factor 1:25 | Last Split Date 2025-11-28 |
1 | 12 Health Care Stocks Moving In Wednesdays Pre-Market Session | 11/19/2025 |
2 | ProMIS Neurosciences Announces Reverse Stock Split | 11/24/2025 |
3 | Insider Trading | 12/03/2025 |
4 | ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimers Disease | 12/18/2025 |
5 | Disposition of 697674 shares by Sclar Jeremy M. of ProMIS Neurosciences subject to Rule 16b-3 | 12/24/2025 |
6 | Market Moves Can ProMIS Neurosciences Inc continue delivering strong returns - Market Growth Summary Low Drawdown Momentum Trade Ideas - baoquankhu1.vn | 01/14/2026 |
7 | Disposition of 697674 shares by Jeremy M. Sclar 2012 Irrevocable Family Trust of ProMIS Neurosciences subject to Rule 16b-3 | 01/28/2026 |
8 | Acquisition by Abg Management Ltd. of 700741 shares of ProMIS Neurosciences at 14.4 subject to Rule 16b-3 | 02/03/2026 |
| Begin Period Cash Flow | 12.6 M | |
| Total Cashflows From Investing Activities | -693.00 |
ProMIS Neurosciences Relative Risk vs. Return Landscape
If you would invest 975.00 in ProMIS Neurosciences on November 9, 2025 and sell it today you would earn a total of 335.00 from holding ProMIS Neurosciences or generate 34.36% return on investment over 90 days. ProMIS Neurosciences is generating 0.75% of daily returns assuming volatility of 7.3436% on return distribution over 90 days investment horizon. In other words, 65% of stocks are less volatile than ProMIS, and above 85% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ProMIS Neurosciences Target Price Odds to finish over Current Price
The tendency of ProMIS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.10 | 90 days | 13.10 | roughly 2.33 |
Based on a normal probability distribution, the odds of ProMIS Neurosciences to move above the current price in 90 days from now is roughly 2.33 (This ProMIS Neurosciences probability density function shows the probability of ProMIS Stock to fall within a particular range of prices over 90 days) .
ProMIS Neurosciences Price Density |
| Price |
Predictive Modules for ProMIS Neurosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ProMIS Neurosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ProMIS Neurosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ProMIS Neurosciences is not an exception. The market had few large corrections towards the ProMIS Neurosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ProMIS Neurosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ProMIS Neurosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.60 | |
β | Beta against Dow Jones | -0.34 | |
σ | Overall volatility | 1.97 | |
Ir | Information ratio | 0.07 |
ProMIS Neurosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ProMIS Neurosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ProMIS Neurosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ProMIS Neurosciences is way too risky over 90 days horizon | |
| ProMIS Neurosciences appears to be risky and price may revert if volatility continues | |
| ProMIS Neurosciences has high likelihood to experience some financial distress in the next 2 years | |
| ProMIS Neurosciences has about 8.95 M in cash with (27.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Abg Management Ltd. of 700741 shares of ProMIS Neurosciences at 14.4 subject to Rule 16b-3 |
ProMIS Neurosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ProMIS Stock often depends not only on the future outlook of the current and potential ProMIS Neurosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ProMIS Neurosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 13.3 M |
ProMIS Neurosciences Fundamentals Growth
ProMIS Stock prices reflect investors' perceptions of the future prospects and financial health of ProMIS Neurosciences, and ProMIS Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProMIS Stock performance.
| Return On Equity | -3.56 | ||||
| Return On Asset | -0.85 | ||||
| Current Valuation | 19.01 M | ||||
| Shares Outstanding | 2.15 M | ||||
| Price To Book | 3.75 X | ||||
| Price To Sales | 5,168 X | ||||
| Gross Profit | (28.34 M) | ||||
| EBITDA | 2.86 M | ||||
| Net Income | 2.78 M | ||||
| Cash And Equivalents | 8.95 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 2.42 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 5.42 X | ||||
| Book Value Per Share | 4.27 X | ||||
| Cash Flow From Operations | (27.18 M) | ||||
| Earnings Per Share | (20.00) X | ||||
| Market Capitalization | 28.2 M | ||||
| Total Asset | 18.91 M | ||||
| Retained Earnings | (90.69 M) | ||||
| Working Capital | 16.69 M | ||||
About ProMIS Neurosciences Performance
By examining ProMIS Neurosciences' fundamental ratios, stakeholders can obtain critical insights into ProMIS Neurosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ProMIS Neurosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.14 | |
| Return On Capital Employed | (0.91) | (0.95) | |
| Return On Assets | 0.13 | 0.14 | |
| Return On Equity | 0.15 | 0.16 |
Things to note about ProMIS Neurosciences performance evaluation
Checking the ongoing alerts about ProMIS Neurosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProMIS Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProMIS Neurosciences is way too risky over 90 days horizon | |
| ProMIS Neurosciences appears to be risky and price may revert if volatility continues | |
| ProMIS Neurosciences has high likelihood to experience some financial distress in the next 2 years | |
| ProMIS Neurosciences has about 8.95 M in cash with (27.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Abg Management Ltd. of 700741 shares of ProMIS Neurosciences at 14.4 subject to Rule 16b-3 |
- Analyzing ProMIS Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProMIS Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining ProMIS Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProMIS Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProMIS Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProMIS Neurosciences' stock. These opinions can provide insight into ProMIS Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could ProMIS diversify its offerings? Factors like these will boost the valuation of ProMIS Neurosciences. Anticipated expansion of ProMIS directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ProMIS Neurosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
ProMIS Neurosciences's market price often diverges from its book value, the accounting figure shown on ProMIS's balance sheet. Smart investors calculate ProMIS Neurosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ProMIS Neurosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ProMIS Neurosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProMIS Neurosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.